Tag: pneumococcal vaccine market research

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Pneumococcal Vaccine Market Evolve in Terms of Growth and Size by 2029?

In recent times, the market size of the pneumococcal vaccine has seen robust growth. The market, which is projected to increase from $8.94 billion in 2024 to $9.4 billion in 2025, is expected to have a compound annual growth rate (CAGR) of 5.2%. Factors such as the discovery of streptococcus pneumoniae, public health apprehensions, initiatives for early vaccination, improvements in healthcare, and alterations in vaccine policy have contributed to its growth over the historical period.

Anticipations are high for a robust expansion in the pneumococcal vaccine market in the upcoming years. It is projected to reach “$11.9 billion in 2029 with a compound annual growth rate (CAGR) of 6.1%.” Contributing factors for this growth forecast include the emergence of new pneumococcal strains, continuous innovation and research, immunization prioritization, increased access to vaccines, and an aging population. Major anticipated trends for the outlook period encompass the development of multivalent vaccines, immunization for high-risk groups, enhancing vaccine efficiency, educational and awareness initiatives, and a focus on infant immunization.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What factors are expected to fuel Pneumococcal Vaccine market growth in the coming years?

The rise in pneumococcal contamination is anticipated to fuel the expansion of the pneumococcal vaccine market. Pneumococcal contamination, which can lead to illnesses such as pneumonia, bloodstream infections, ear infections, and sinus infections, is brought about by the Streptococcus pneumoniae, or pneumococcus bacteria. The pneumococcal vaccine works by triggering the body to create antibodies to fight off the pneumococcal bacteria, ultimately reducing or eliminating disease-bearing bacteria and toxins. This offers protection against numerous pneumococcal infections, especially in children, the elderly, and immunocompromised individuals. For instance, data from the US-based public health agency, the Center for Disease Control and Prevention, reported in January 2022, that Pneumococcal pneumonia leads to an estimated 150,000 hospitalizations annually in the United States, making up to 30% of adult community-acquired pneumonia. Thus, this escalating rate of pneumococcal contamination is a significant driver for the growth of the pneumococcal vaccine market.

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Trends Are Currently Influencing Growth In The Pneumococcal Vaccine Market?

Leading corporations in the pneumococcal vaccine market are focusing on product innovation to enhance their market profitability. For instance, the US-based pharmaceutical firm, Merck & Co Inc., launched a new vaccine called V116 in July 2023. This vaccine is designed to target the eight unique serotypes of Streptococcus pneumoniae, which cause most cases of adult pneumococcal disease. V116 demonstrated superior immunogenicity across various serotypes in adults compared to its rivals. Moreover, it exhibited positive immune responses in both individuals with prior vaccination and those without. The U.S. Food and Drug Administration (FDA) has given it a breakthrough therapy status and is in the process of its Phase 3 development.

What Are The Most Active Companies In The Pneumococcal Vaccine Market Today?

Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Regional Markets Are Attracting The Most Investment In Pneumococcal Vaccine?

North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Pneumococcal Vaccine Market Evolve in Terms of Growth and Size by 2029?

In recent times, the market size of the pneumococcal vaccine has seen robust growth. The market, which is projected to increase from $8.94 billion in 2024 to $9.4 billion in 2025, is expected to have a compound annual growth rate (CAGR) of 5.2%. Factors such as the discovery of streptococcus pneumoniae, public health apprehensions, initiatives for early vaccination, improvements in healthcare, and alterations in vaccine policy have contributed to its growth over the historical period.

Anticipations are high for a robust expansion in the pneumococcal vaccine market in the upcoming years. It is projected to reach “$11.9 billion in 2029 with a compound annual growth rate (CAGR) of 6.1%.” Contributing factors for this growth forecast include the emergence of new pneumococcal strains, continuous innovation and research, immunization prioritization, increased access to vaccines, and an aging population. Major anticipated trends for the outlook period encompass the development of multivalent vaccines, immunization for high-risk groups, enhancing vaccine efficiency, educational and awareness initiatives, and a focus on infant immunization.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What factors are expected to fuel Pneumococcal Vaccine market growth in the coming years?

The rise in pneumococcal contamination is anticipated to fuel the expansion of the pneumococcal vaccine market. Pneumococcal contamination, which can lead to illnesses such as pneumonia, bloodstream infections, ear infections, and sinus infections, is brought about by the Streptococcus pneumoniae, or pneumococcus bacteria. The pneumococcal vaccine works by triggering the body to create antibodies to fight off the pneumococcal bacteria, ultimately reducing or eliminating disease-bearing bacteria and toxins. This offers protection against numerous pneumococcal infections, especially in children, the elderly, and immunocompromised individuals. For instance, data from the US-based public health agency, the Center for Disease Control and Prevention, reported in January 2022, that Pneumococcal pneumonia leads to an estimated 150,000 hospitalizations annually in the United States, making up to 30% of adult community-acquired pneumonia. Thus, this escalating rate of pneumococcal contamination is a significant driver for the growth of the pneumococcal vaccine market.

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Trends Are Currently Influencing Growth In The Pneumococcal Vaccine Market?

Leading corporations in the pneumococcal vaccine market are focusing on product innovation to enhance their market profitability. For instance, the US-based pharmaceutical firm, Merck & Co Inc., launched a new vaccine called V116 in July 2023. This vaccine is designed to target the eight unique serotypes of Streptococcus pneumoniae, which cause most cases of adult pneumococcal disease. V116 demonstrated superior immunogenicity across various serotypes in adults compared to its rivals. Moreover, it exhibited positive immune responses in both individuals with prior vaccination and those without. The U.S. Food and Drug Administration (FDA) has given it a breakthrough therapy status and is in the process of its Phase 3 development.

What Are The Most Active Companies In The Pneumococcal Vaccine Market Today?

Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Regional Markets Are Attracting The Most Investment In Pneumococcal Vaccine?

North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Pneumococcal Vaccine Market Evolve in Terms of Growth and Size by 2029?

In recent times, the market size of the pneumococcal vaccine has seen robust growth. The market, which is projected to increase from $8.94 billion in 2024 to $9.4 billion in 2025, is expected to have a compound annual growth rate (CAGR) of 5.2%. Factors such as the discovery of streptococcus pneumoniae, public health apprehensions, initiatives for early vaccination, improvements in healthcare, and alterations in vaccine policy have contributed to its growth over the historical period.

Anticipations are high for a robust expansion in the pneumococcal vaccine market in the upcoming years. It is projected to reach “$11.9 billion in 2029 with a compound annual growth rate (CAGR) of 6.1%.” Contributing factors for this growth forecast include the emergence of new pneumococcal strains, continuous innovation and research, immunization prioritization, increased access to vaccines, and an aging population. Major anticipated trends for the outlook period encompass the development of multivalent vaccines, immunization for high-risk groups, enhancing vaccine efficiency, educational and awareness initiatives, and a focus on infant immunization.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What factors are expected to fuel Pneumococcal Vaccine market growth in the coming years?

The rise in pneumococcal contamination is anticipated to fuel the expansion of the pneumococcal vaccine market. Pneumococcal contamination, which can lead to illnesses such as pneumonia, bloodstream infections, ear infections, and sinus infections, is brought about by the Streptococcus pneumoniae, or pneumococcus bacteria. The pneumococcal vaccine works by triggering the body to create antibodies to fight off the pneumococcal bacteria, ultimately reducing or eliminating disease-bearing bacteria and toxins. This offers protection against numerous pneumococcal infections, especially in children, the elderly, and immunocompromised individuals. For instance, data from the US-based public health agency, the Center for Disease Control and Prevention, reported in January 2022, that Pneumococcal pneumonia leads to an estimated 150,000 hospitalizations annually in the United States, making up to 30% of adult community-acquired pneumonia. Thus, this escalating rate of pneumococcal contamination is a significant driver for the growth of the pneumococcal vaccine market.

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Trends Are Currently Influencing Growth In The Pneumococcal Vaccine Market?

Leading corporations in the pneumococcal vaccine market are focusing on product innovation to enhance their market profitability. For instance, the US-based pharmaceutical firm, Merck & Co Inc., launched a new vaccine called V116 in July 2023. This vaccine is designed to target the eight unique serotypes of Streptococcus pneumoniae, which cause most cases of adult pneumococcal disease. V116 demonstrated superior immunogenicity across various serotypes in adults compared to its rivals. Moreover, it exhibited positive immune responses in both individuals with prior vaccination and those without. The U.S. Food and Drug Administration (FDA) has given it a breakthrough therapy status and is in the process of its Phase 3 development.

What Are The Most Active Companies In The Pneumococcal Vaccine Market Today?

Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Regional Markets Are Attracting The Most Investment In Pneumococcal Vaccine?

North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Pneumococcal Vaccine Market Evolve in Terms of Growth and Size by 2029?

In recent times, the market size of the pneumococcal vaccine has seen robust growth. The market, which is projected to increase from $8.94 billion in 2024 to $9.4 billion in 2025, is expected to have a compound annual growth rate (CAGR) of 5.2%. Factors such as the discovery of streptococcus pneumoniae, public health apprehensions, initiatives for early vaccination, improvements in healthcare, and alterations in vaccine policy have contributed to its growth over the historical period.

Anticipations are high for a robust expansion in the pneumococcal vaccine market in the upcoming years. It is projected to reach “$11.9 billion in 2029 with a compound annual growth rate (CAGR) of 6.1%.” Contributing factors for this growth forecast include the emergence of new pneumococcal strains, continuous innovation and research, immunization prioritization, increased access to vaccines, and an aging population. Major anticipated trends for the outlook period encompass the development of multivalent vaccines, immunization for high-risk groups, enhancing vaccine efficiency, educational and awareness initiatives, and a focus on infant immunization.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What factors are expected to fuel Pneumococcal Vaccine market growth in the coming years?

The rise in pneumococcal contamination is anticipated to fuel the expansion of the pneumococcal vaccine market. Pneumococcal contamination, which can lead to illnesses such as pneumonia, bloodstream infections, ear infections, and sinus infections, is brought about by the Streptococcus pneumoniae, or pneumococcus bacteria. The pneumococcal vaccine works by triggering the body to create antibodies to fight off the pneumococcal bacteria, ultimately reducing or eliminating disease-bearing bacteria and toxins. This offers protection against numerous pneumococcal infections, especially in children, the elderly, and immunocompromised individuals. For instance, data from the US-based public health agency, the Center for Disease Control and Prevention, reported in January 2022, that Pneumococcal pneumonia leads to an estimated 150,000 hospitalizations annually in the United States, making up to 30% of adult community-acquired pneumonia. Thus, this escalating rate of pneumococcal contamination is a significant driver for the growth of the pneumococcal vaccine market.

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Trends Are Currently Influencing Growth In The Pneumococcal Vaccine Market?

Leading corporations in the pneumococcal vaccine market are focusing on product innovation to enhance their market profitability. For instance, the US-based pharmaceutical firm, Merck & Co Inc., launched a new vaccine called V116 in July 2023. This vaccine is designed to target the eight unique serotypes of Streptococcus pneumoniae, which cause most cases of adult pneumococcal disease. V116 demonstrated superior immunogenicity across various serotypes in adults compared to its rivals. Moreover, it exhibited positive immune responses in both individuals with prior vaccination and those without. The U.S. Food and Drug Administration (FDA) has given it a breakthrough therapy status and is in the process of its Phase 3 development.

What Are The Most Active Companies In The Pneumococcal Vaccine Market Today?

Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Regional Markets Are Attracting The Most Investment In Pneumococcal Vaccine?

North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Pneumococcal Vaccine Market Valued at Present and by 2029?

The market size for the pneumococcal vaccine has seen considerable growth in the past few years. This expansion is predicted to continue with it projected to increase from $8.94 billion in 2024 to $9.4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.2%. The substantial growth observed during the historical period can be tied to developments such as the discovery of streptococcus pneumoniae, public health consciousness, implementation of early vaccination programs, advancements in health care, and modifications in vaccine policies.

The market for pneumococcal vaccines is projected to witness significant expansion in the upcoming years, escalating to a valuation of $11.9 billion by 2029 with a CAGR of 6.1%. The anticipated growth during the forecast period can be ascribed to factors such as the emergence of new pneumococcal strains, ongoing research and development initiatives, emphasis on immunization, broadening availability of vaccines and the aging population. Key trends identified for the forecast period comprise the development of multivalent vaccines, focus on vaccinating the high-risk group, enhancing the efficacy of vaccines, initiatives to increase education and awareness, with particular attention to infant immunization.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

#What Drivers Are Influencing Growth In The Pneumococcal Vaccine Market?

The rise in cases of pneumococcal contamination is anticipated to fuel the development of the pneumococcal vaccine market. Pneumococcal contamination, namely infections caused by the bacteria Streptococcus pneumoniae or pneumococcus, consists of pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine encourages the generation of antibodies to fight pneumococcal bacteria, reducing or eradicating bacteria and toxins that cause diseases, thereby safeguarding children, older adults, and those with compromised immune systems from various pneumococcal infections. As an illustration, the Center for Disease Control and Prevention, a US public health organization, stated in January 2022 that Pneumococcal pneumonia results in around 150,000 hospitalizations annually in the United States, representing approximately 30% of adult community-acquired pneumonia. Hence, the ascending incidence of pneumococcal contamination is stimulating the expansion of the pneumococcal vaccine market.

What Are The Main Segments Identified In The Pneumococcal Vaccine Market Research?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Are The Leading Trends And Opportunities In The Pneumococcal Vaccine Sector?

Technological advancements are emerging as a significant trend in the pharmaceutical continuous manufacturing market, with leading industry players introducing new offerings aimed at maintaining their market positions. For instance, in December 2022, The United States Pharmacopeia (USP) unveiled the USP Advanced Manufacturing Technology Lab as well as research and development analytical solutions. This US-based non-profit organization holds both the trademark and copyright for the Pharmacopeia National Formulary (USP-NF). The role of these analytical lab services is to help drug manufacturers embrace sophisticated manufacturing technologies like pharmaceutical continuous manufacturing (PCM). This not only broadens the geographic diversity in pharmaceutical production but also enhances the resilience of the medicine supply chain. It involves describing materials, creating and qualifying methods to support and ensure the quality of PCM-based drugs.

Which Companies Play A Key Role In The Development Of The Pneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

What Are The Key Regional Developments Shaping The Pneumococcal Vaccine Market?

North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Pneumococcal Vaccine Market Size Changed, over the years?

The market size for the pneumococcal vaccine has seen robust growth in recent years. The market is projected to expand from $8.94 billion in 2024 to $9.49 billion in 2025, with a compound annual growth rate (CAGR) of 6.2%. Factors contributing to this growth during the historic period include the discovery of streptococcus pneumoniae, public health concerns, initiatives for early vaccination, advancements in healthcare, and modifications in vaccine policies.

How Much Will the Pneumococcal Vaccine Market Be Worth in 2029?

A significant expansion is anticipated in the pneumococcal vaccine market in the coming years, with projections showing growth to $12.12 billion by 2029, indicative of a compound annual growth rate (CAGR) of 6.3%. Factors contributing to this forecasted growth span from the evolution of pneumococcal strains, ongoing research and development efforts, immunization priorities, enhanced vaccine accessibility, to aging populations. Key trends expected to emerge during this forecast period encompass the development of multivalent vaccines, focusing on vaccination for high-risk groups, efforts to enhance vaccine effectiveness, proliferating education and awareness campaigns, and prioritizing infant immunization.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

Which is the Largest Company in the Pneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

What Are the Main Market Drivers in the Pneumococcal Vaccine Industry?

The escalating incidence of pneumococcal infections is anticipated to fuel the expansion of the pneumococcal vaccine market. Pneumococcal infections, caused by the bacterium Streptococcus pneumoniae or pneumococcus, encompass diseases like pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine encourages the body to generate antibodies that will counteract these bacteria, minimizing or eliminating the bacteria and toxins that cause disease. This protects vulnerable groups such as children, the elderly, and those with compromised immune systems from various types of pneumococcal diseases. For instance, as of January 2022, the US Center for Disease Control and Prevention reported that Pneumococcal pneumonia alone is responsible for an estimated 150,000 hospitalizations annually in the United States, making up to 30% of adult community-acquired pneumonia. Hence, the rising incidence of pneumococcal contamination is contributing to the growth of the pneumococcal vaccine market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

How Is the Pneumococcal Vaccine Market Segments Structured?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Strategic Trends Are Transforming the Pneumococcal Vaccine Market?

Top companies in the pneumococcal vaccine market are launching innovative products to boost their market gains. For instance, the US-based pharmaceutical firm, Merck & Co Inc., unveiled the V116 vaccine in July 2023. The vaccine is designed to treat eight unique serotypes of Streptococcus pneumoniae, the main cause of adult pneumococcal disease. When compared to other similar vaccines, V116 has demonstrated superior immunogenicity across multiple serotypes in adults, and has yielded positive immune reactions in both individuals with no prior vaccination history and those previously vaccinated. The U.S. Food and Drug Administration (FDA) has labelled V116 as a breakthrough therapy and it is presently in the third phase of development.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Global Regions Offer the Highest Growth in the Pneumococcal Vaccine Market?

North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11950

This Report Delivers Insight On:

1. How big is the pneumococcal vaccine market, and how is it changing globally?

2. Who are the major companies in the pneumococcal vaccine market, and how are they performing?

3. What are the key opportunities and risks in the pneumococcal vaccine market right now?

4. Which products or customer segments are growing the most in the pneumococcal vaccine market?

5. What factors are helping or slowing down the growth of the pneumococcal vaccine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Are the Primary Drivers Supporting the Market Growth of thePneumococcal Vaccine Market?

The surge in cases of pneumococcal contamination is projected to boost the growth of the pneumococcal vaccine market. Pneumococcal contamination signifies any infection instigated by the bacteria Streptococcus pneumoniae, or pneumococcus. These infections can be manifested as pneumonia, bloodstream infections, ear infections, or sinus infections. The pneumococcal vaccine plays a significant role by urging the body to generate antibodies to counter pneumococcal bacteria, thereby minimizing or eliminating bacteria and toxins responsible for infections. This course of action thereby protects children, elderly people, and those with compromised immune systems against various types of pneumococcal infections. As per a report by the Center for Disease Control and Prevention in January 2022, Pneumococcal pneumonia results in an estimated 150,000 hospitalizations every year within the United States, representing up to 30% of community-acquired pneumonia in adults. Therefore, the rise in instances of pneumococcal contamination is contributing to the development of the pneumococcal vaccine market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

How Has the Pneumococcal Vaccine Market Evolved in Recent Years, and What are the Growth Projections for the Forecast Period?

In recent times, the pneumococcal vaccine market has seen substantial growth. The market, which stood at $8.94 billion in 2024, is projected to increase to $9.49 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.2%. The notable expansion during the historic period can be associated with factors such as the discovery of streptococcus pneumoniae, public health concern, initiatives towards early vaccination, advancements in healthcare, and alterations in vaccine policies.

In the coming years, the pneumococcal vaccine market is predicted to experience robust growth. The market is projected to expand to a size of $12.12 billion by 2029, with a compound annual growth rate (CAGR) of 6.3%. Factors contributing to the growth during the projected period include the emergence of new pneumococcal strains, ongoing research and development, prioritizing immunization, increasing vaccine access, and aging population. Prominent trends anticipated during this term include the development of multivalent vaccines, vaccination of high-risk groups, enhancing vaccine effectiveness, promoting caution and knowledge through campaigns, and focusing on infant immunization.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11950

What Are the Latest Innovations Influencing thePneumococcal Vaccine Market?

In an effort to boost their profitability, key players in the pneumococcal vaccine market are pioneering new products. Notably, Merck & Co Inc., an American pharmaceutical entity, introduced the V116 vaccine in July 2023. Conceived to tackle the eight unique serotypes of Streptococcus pneumoniae primarily causing adult pneumococcal diseases, V116 outperforms other pneumococcal vaccines in terms of immunogenicity towards various serotypes in adult demographics. Additionally, it has generated favorable immune reactions in both individuals receiving vaccination for the first time and those previously vaccinated. Currently undergoing Phase 3 development, V116 has been accorded breakthrough therapy status by the U.S Food and Drug Administration (FDA).

Who Are the Major Industry Players Accelerating Growth in thePneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Primary Segments of the Pneumococcal Vaccine Market Are Driving Growth and Industry Transformations?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of thePneumococcal Vaccine Market?# Market?

North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Gobal Pneumococcal Vaccine Maret 2025, By The Business Research Company:

Medical Waste Management Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-waste-management-global-market-report

Medical Device Cleaning Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-device-cleaning-global-market-report

Medical Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the pneumococcal vaccine market?

In recent times, the market size for the pneumococcal vaccine has shown a potent growth. The market, which is anticipated to increase from a worth of $8.94 billion in 2024 to $9.49 billion in 2025, enjoys a compound annual growth rate (CAGR) of 6.2%. This remarkable growth in the past is due to various factors including the discovery of streptococcus pneumoniae, public health interest, early vaccination initiatives, advancements in healthcare, and alterations in vaccine policies.

What will be the pneumococcal vaccine market size in the future?

The market size for the pneumococcal vaccine is predicted to experience significant expansion in the coming years, increasing to a value of $12.12 billion by 2029, with a compound annual growth rate (CAGR) of 6.3%. Various factors contributing to this forecasted growth include the evolution of pneumococcal strains, ongoing research and development efforts, prioritizing immunization, broadening vaccine accessibility, and an aging population. Notable trends for this period involve development of multivalent vaccines, focusing on vaccination for high-risk groups, enhancing the effectiveness of vaccines, intensifying education and awareness initiatives, and a specific focus on infant immunization.

Get your pneumococcal vaccine market report here!

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

What main drivers are fueling expansion in the pneumococcal vaccine market?

The escalating occurrence of pneumococcal infections is anticipated to drive the pneumococcal vaccine market’s expansion. Pneumococcal infections encompass any disease brought on by the bacteria known as Streptococcus pneumoniae or pneumococcus, including conditions such as pneumonia, bloodstream infections, ear, and sinus infections. The pneumococcal vaccine prompts the body to create antibodies against the pneumococcal bacteria, reducing or eliminating bacteria and toxins that cause disease, hence safeguarding children, seniors, and individuals with compromised immune systems against numerous types of pneumococcal infections. For example, the Center for Disease Control and Prevention, a US public health agency, reported an estimate of 150,000 hospital admissions due to pneumococcal pneumonia per year in January 2022, which represents up to 30% of adult-acquired pneumonia cases within the community. Thus, the rising prevalence of pneumococcal contamination fuels the pneumococcal vaccine market’s growth.

What key areas define the segmentation of the global pneumococcal vaccine market?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

Who are the dominant players expanding their reach in the pneumococcal vaccine market?

Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

How are evolving market trends shaping pneumococcal vaccine Strategies?

Leading companies in the pneumococcal vaccine market are introducing innovative products to enhance their market profitability. For instance, in July 2023, Merck & Co Inc., an American pharmaceutical firm, introduced the V116 vaccine. This vaccine is designed to combat the eight unique serotypes of Streptococcus pneumoniae that are predominantly accountable for adult pneumococcal disease. When compared to other pneumococcal vaccines, V116 has demonstrated superior immunogenicity across various serotypes in adults, and has also elicited favourable immune responses in both individuals with no prior vaccination and those who were previously vaccinated. The U.S. Food and Drug Administration (FDA) has classified V116 as a breakthrough therapy, and it is currently undergoing Phase 3 development.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11950

Which regions are emerging as leaders in the pneumococcal vaccine market?

North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Medical Waste Management Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-waste-management-global-market-report

Medical Device Cleaning Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-device-cleaning-global-market-report

Medical Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Pneumococcal Vaccine Market’s Growth Rate Evolve Over the Forecast Period to 2034?

The pneumococcal vaccine market has grown steadily in recent years. It is expected to rise from $8.94 billion in 2024 to $9.49 billion in 2025, at a CAGR of 6.2%. The historical growth of this market has been driven by the discovery of Streptococcus pneumoniae, concerns regarding public health, early vaccination initiatives, advancements in healthcare, and changes in vaccine policies.

The pneumococcal vaccine market is anticipated to witness significant growth, reaching $12.12 billion by 2029 with a CAGR of 6.3%. This expansion is driven by evolving pneumococcal strains, ongoing research and development, shifting immunization priorities, broader vaccine accessibility, and an aging population. Key trends expected include multivalent vaccine development, targeted immunization strategies, improved vaccine efficacy, educational campaigns, and a focus on infant vaccination.

What Industry-Specific Factors Are Fueling the Growth of the pneumococcal vaccine Market?

The growing prevalence of pneumococcal infections is expected to accelerate the growth of the pneumococcal vaccine market. Pneumococcal infections, caused by the Streptococcus pneumoniae bacterium, can lead to diseases such as pneumonia, bloodstream infections, and ear infections. Pneumococcal vaccines help the body produce antibodies to combat these infections. For example, in January 2022, the U.S. Centers for Disease Control and Prevention reported that pneumococcal pneumonia leads to around 150,000 hospitalizations annually, accounting for up to 30% of adult community-acquired pneumonia cases. Thus, the rising prevalence of pneumococcal infections is promoting growth in the pneumococcal vaccine market.

Request Your Free Pneumococcal Vaccine Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

Who Are the Influential Players Reshaping the Pneumococcal Vaccine Market Landscape?

Major companies operating in the pneumococcal vaccine market include:

• Pfizer Inc._x000D_

• Johnson & Johnson_x000D_

• Merck & Co. Inc._x000D_

• Sanofi S.A._x000D_

• GlaxoSmithKline plc_x000D_

What New and Evolving Trends Are Having a Lasting Impact on the Pneumococcal Vaccine Market?

Companies in the pneumococcal vaccine market are innovating to boost profitability. For example, in July 2023, Merck & Co Inc., a US-based pharmaceutical company, launched the V116 vaccine, aimed at targeting eight distinct serotypes of Streptococcus pneumoniae that cause adult pneumococcal disease. Compared to other pneumococcal vaccines, V116 has demonstrated superior immunogenicity in adult populations, producing positive immune responses in both vaccine-naïve and previously vaccinated individuals. The U.S. Food and Drug Administration (FDA) has designated V116 as a breakthrough therapy, and it is currently in Phase 3 development.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Segments of the Pneumococcal Vaccine Market Hold the Most Potential for Future Development?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

Which Geographic Locations Are Critical to the Growth of the Pneumococcal Vaccine Market?

North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Defining Aspects of the Pneumococcal Vaccine Market Landscape?

The pneumococcal vaccine refers to a vaccination that offers defense against potentially fatal and severe pneumococcal infections caused by streptococcus pneumoniae bacteria, such as pneumonia, meningitis, and sepsis. It is highly efficient in protecting infants from one of the most common causes of meningitis and other illnesses, such as acute ear infections.

Browse Through More Similar Reports By The Business Research Company:

Medical Waste Management Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-waste-management-global-market-report

Medical Device Cleaning Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-device-cleaning-global-market-report

Medical Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: